What the Data Says Directly
Based on available Phase 3 clinical trial data, tirzepatide produces greater average weight loss than semaglutide, which produces greater average weight loss than liraglutide. The ranking by efficacy is: tirzepatide (20%+ average) above semaglutide (15% average) above liraglutide (5-8% average). Retatrutide, in Phase 2 trials, has shown results exceeding tirzepatide — but it is not yet approved or commercially available.
If the question is purely "which approved GLP-1 produces the most weight loss on average," the answer is tirzepatide. That is not a marketing claim — it is the head-to-head conclusion from the SURMOUNT versus STEP trial data, and from early head-to-head comparative studies.
Why "Best" Is More Complicated Than It Sounds
Average weight loss in a clinical trial tells you what a large population of patients experienced. It does not tell you what you will experience. Individual response to GLP-1 therapy varies based on genetics, baseline metabolic health, gut microbiome, adherence, titration management, and protein intake and training behavior. The patient who loses 25% on semaglutide is not doing something wrong — their individual response to that molecule was excellent.
Access also matters. Tirzepatide has greater average efficacy — but if access to compounded tirzepatide is restricted, unavailable, or significantly more expensive for your specific situation, that efficacy advantage may not translate into a practical advantage for you. A drug you can consistently access and afford is more effective, in practice, than one you cannot.
"The best GLP-1 is the one you can access, tolerate, and use consistently under proper clinical oversight. The trial averages are where the conversation starts — they are not where it ends."
For Most Patients Starting Today: The Practical Answer
For patients beginning a GLP-1 protocol without a prior GLP-1 history, compounded semaglutide is the standard starting recommendation — the deepest evidence base, widest availability, established titration protocols, and meaningful efficacy. Patients who want to push further from the outset, who have already tried semaglutide without adequate response, or who are working with a provider toward more aggressive body composition goals, are appropriate candidates for a tirzepatide conversation.
The answer to "which is best" for you specifically is a clinical determination made with a licensed provider who knows your history. What the data gives you is the framework for that conversation — not a substitute for it.
A licensed provider determines candidacy.
503B sourced. All 50 states.